Abstract 289P
Background
Palliative chemotherapy is the standard of care for patients with advanced nasopharyngeal carcinoma. Radiotherapy may be offered for patients who responded to chemotherapy for local control. However, the dose and fractionation schedules used varies between oncologists.
Methods
An online survey via email was conducted for all practicing oncologists in public hospitals in Malaysia. The questionnaires were sent to 42 oncologists. The questionnaires gathered data on their practice in giving radiotherapy to patients with advanced nasopharyngeal carcinoma who responded to palliative chemotherapy,.
Results
33 oncologists responded to the questionnaire, which gave a response rate of 78.5%. Most oncologists (85%) will give radiotherapy if patients responded to palliative chemotherapy, and 90.9% will give radiotherapy alone without concurrent chemotherapy. The radiotherapy dose fractionation schedules vary among the oncologists, with 55Gy/20 fractions/4 weeks the commonest fractionation used (30.3%), followed by 40Gy/15 fractions/3 weeks (24.2%), and 9.1% choosing schedules such 30Gy/10 fractions/2 weeks, 45Gy/15 fractions/3 weeks, and 70Gy/35 fractions/7 weeks. The other fractionations used are 52Gy/13 fractions/2.5 weeks, 50Gy/25 fractions/5 weeks, 60Gy/25 fractions/5 weeks, 66Gy/33 fractions/6.5 weeks, and 60Gy/30 fractions/6 weeks. Most oncologists will prefer a fractionation schedules of 3-4 weeks duration (75.8%), with high enough dose to give a good local control and avoiding long treatment duration, as the radiotherapy is non-curative in nature.
Conclusions
There are currently no guidelines or consensus on the optimum radiotherapy dose fractionation schedules for this group of patients. The decision for the preferred dose-fractionation schedules have to take into consideration factors such as symptoms, disease extent and comorbidity. An optimum dose-fractionation schedule which does not prolong the treatment duration and giving the best local control is very much needed, especially in situations such as the current COVID-19 pandemic.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Lymph nodes metastasis is the most important factor associated with pattern of recurrence following curative resection of gastric adenocarcinoma
Presenter: Fu-Hai Wang
Session: e-Poster Display Session
144P - Clinical implication of DNA damage response gene in patients with stage II or III gastric cancer
Presenter: In Gyu Hwang
Session: e-Poster Display Session
145P - A nomogram for predicting the benefit of adjuvant chemotherapy after resection in patients with Borrmann type IV gastric cancer
Presenter: Qing-Zhu Qiu
Session: e-Poster Display Session
146P - Red cell distribution width and mean corpuscular volume ratio as a promising new marker for chemotherapy effects in remnant gastric cancer: An analysis of a multi-institutional database
Presenter: Kai-Xiang Xu
Session: e-Poster Display Session
147P - Can the clinical stage of the 8th edition of the Union for International Cancer Control TNM classification stratify prognosis of patients with Siewert type II/III cancer?
Presenter: Hayato Watanabe
Session: e-Poster Display Session
148P - MCV-the ideal answer to predict the prognosis of remnant gastric cancer: An analysis from a multi-institutional database
Presenter: Kai Weng
Session: e-Poster Display Session
149P - Molecular and clinical characteristics of patients with resectable gastric cancer
Presenter: Zhi Zheng
Session: e-Poster Display Session
150P - Real-world assessment of the treatment patterns associated with unresectable advanced and metastatic gastric cancer in China
Presenter: Xiao Sun
Session: e-Poster Display Session
151P - Treatment patterns, healthcare resource use, economic and survival outcomes associated with unresectable advanced metastatic gastric cancers in Taiwan
Presenter: Chee Jen Chang
Session: e-Poster Display Session
152P - ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation
Presenter: Koji Kase
Session: e-Poster Display Session